The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Rafael Rosell

Laboratory of Molecular Biology of Cancer

University Hospital Germans Trias i Pujol

Barcelona

Spain

[email]@ns.hugtip.scs.es

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Laboratory of Molecular Biology of Cancer, University Hospital Germans Trias i Pujol, Barcelona, Spain. 1999 - 2005
  • Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, E-08916, Spain. 2001 - 2005
  • Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. 2000 - 2004

References

  1. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Rosell, R., Ichinose, Y., Taron, M., Sarries, C., Queralt, C., Mendez, P., Sanchez, J.M., Nishiyama, K., Moran, T., Cirauqui, B., Mate, J.L., Besse, B., Reguart, N., Perez, M., Sanchez, J.J. Lung. Cancer (2005) [Pubmed]
  2. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Rosell, R., Felip, E., Reguart, N., Moran, T. Future. Oncology. (london,. England) (2005) [Pubmed]
  3. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., Artal, A. Clin. Cancer Res. (2004) [Pubmed]
  4. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Rosell, R., Felip, E., Taron, M., Majo, J., Mendez, P., Sanchez-Ronco, M., Queralt, C., Sanchez, J.J., Maestre, J. Clin. Cancer Res. (2004) [Pubmed]
  5. Pemetrexed in previously treated non-small-cell lung cancer. Rosell, R., Sanchez, J.M., Taron, M., Moran, T., Ciuraqui, B., Canela, M., Felip, E., Massuti, B., Camps, C. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  6. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Rosell, R., Felip, E., Garcia-Campelo, R., Balaña, C. Lung. Cancer (2004) [Pubmed]
  7. The promise of pharmacogenomics: gemcitabine and pemetrexed. Rosell, R., Taron, M., Sanchez, J.M., Moran, T., Reguart, N., Besse, B., Isla, D., Massuti, B., Alberola, V., Sanchez, J.J. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  8. Genetic testing for chemotherapy in non-small cell lung cancer. Rosell, R., Taron, M., Alberola, V., Massuti, B., Felip, E. Lung. Cancer (2003) [Pubmed]
  9. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Rosell, R., Taron, M., Barnadas, A., Scagliotti, G., Sarries, C., Roig, B. Cancer. Control (2003) [Pubmed]
  10. Influence of genetic markers on survival in non-small cell lung cancer. Rosell, R., Taron, M., Camps, C., López-Vivanco, G. Drugs. Today (2003) [Pubmed]
  11. Translational oncogenomics: toward rational therapeutic decision-making. Rosell, R., Monzo, M., O'Brate, A., Taron, M. Curr. Opin. Oncol (2002) [Pubmed]
  12. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Rosell, R., Gatzemeier, U., Betticher, D.C., Keppler, U., Macha, H.N., Pirker, R., Berthet, P., Breau, J.L., Lianes, P., Nicholson, M., Ardizzoni, A., Chemaissani, A., Bogaerts, J., Gallant, G. Ann. Oncol. (2002) [Pubmed]
  13. DNA repair and cisplatin resistance in non-small-cell lung cancer. Rosell, R., Lord, R.V., Taron, M., Reguart, N. Lung. Cancer (2002) [Pubmed]
  14. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Rosell, R., Fossella, F., Milas, L. Lung. Cancer (2002) [Pubmed]
  15. Predictive molecular markers in non-small cell lung cancer. Rosell, R., Tarón, M., O'Brate, A. Curr. Opin. Oncol (2001) [Pubmed]
  16. Meeting Report of the Seventh IASLC Lung Cancer Biology Workshop: Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer, Barcelona, Spain, April 30- May 3, 2001. Rosell, R., Saijo, N. Lung. Cancer (2001) [Pubmed]
  17. Role of multimodality treatment for lung cancer. Rosell, R., Felip, E. Semin. Surg. Oncol (2000) [Pubmed]
  18. Genetic susceptibility associated with rare HRAS1 variable number of tandem repeats alleles in Spanish non-small cell lung cancer patients. Rosell, R., Calvo, R., Sánchez, J.J., Maurel, J., Guillot, M., Monzó, M., Núñez, L., Barnadas, A. Clin. Cancer Res. (1999) [Pubmed]
  19. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Rosell, R., Gómez-Codina, J., Camps, C., Javier Sánchez, J., Maestre, J., Padilla, J., Cantó, A., Abad, A., Roig, J. Lung. Cancer (1999) [Pubmed]
  20. Ifosfamide in non-small-cell lung cancer. Rosell, R., Martin, C., Balaña, C. Ann. Oncol. (1999) [Pubmed]
 
WikiGenes - Universities